BIOMAT Database Logo BIOMAT Database Logo

Prognostic impact of CD45 antigen expression in high-risk, childhood B-cell precursor acute lymphoblastic leukemia. 2001

A Nakamura, and M Tsurusawa, and A Kato, and T Taga, and Y Hatae, and M Miyake, and J Mimaya, and N Onodera, and A Watanabe, and T Watanabe, and H Kanegane, and T Matsushita, and A Iwai, and N Hyakuna, and K Gushi, and T Kawakami, and I Sekine, and O Izichi, and K Asami, and A Kikuta, and A Tanaka, and T Fujimoto, and
Department of Pediatrics, Aichi Medical University, Aichi, 480-1195 Japan.

To evaluate the clinical implications of CD45 expression in acute childhood lymphoblastic leukemia (ALL), we measured the CD45 expression of blast cells from 133 untreated patients with childhood B-precursor ALL (n = 118) or T-ALL (n = 15). CD45 expression (> or = 20%) was detected in all 15 cases (100%) of T-ALL, and 101 cases (86%) of B-precursor ALL. In 122 cases, the fluorescence intensity of the CD45 expression was measured as a relative value; the ratio of average linear values (RALV) of CD45 on the blasts to that on CD3-positive T-lymphocytes from the same specimen. The expression was more intense in the T-ALL cases than in the B-precursor ALL cases (RALV, mean +/- SE: T-ALL 0.230 +/- 0.04 vs. pro-B ALL 0.150 +/- 0.012/pre-B ALL 0.153 +/- 0.019, p < 0.05). However, the intensity of the CD10, CD19, CD20 and CD34 antigen immunoreactivity did not correlate with the CD45 expression. Patients with hyperdiploidy (chromosome number > 50) showed significantly lower levels of CD45 expression than patients with t(1;19) or normal karyotypes (RALV, mean +/- SE: 0.081 +/- 0.022 vs. 0.133 +/- 0.03/0.143 +/- 0.019, p < 0.05). Other clinical features such as age, gender and WBC count did not correlate with CD45 expression. The prognostic implications of CD45 expression were studied in non-high-risk (low-risk + intermediate-risk) (n = 60) and high-risk patients (n = 52) with B-precursor ALL who had been treated with the risk-directed protocol of ALL-941 trial. Although CD45 expression did not correlate with the event-free survival (EFS) of the non-high-risk patients, there was a significant correlation between the expression levels and the EFS of the high-risk patients: the 3-year EFS rate of the CD45low group (n = 26, RALV = 0.017-0.132) was 88 +/- 7% versus the CD45high group (n = 26, RALV = 0.133-0.450) at 34 +/- 24% (p < 0.05). These results show that the levels of expression of the CD45 antigen on leukemic lymphoblasts are significantly correlated with the clinical features and prognosis of childhood ALL.

UI MeSH Term Description Entries
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D001215 Asparaginase A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1. Asparaginase II,Asparaginase medac,Asparagine Deaminase,Colaspase,Crasnitin,Elspar,Erwinase,Kidrolase,Leunase,Paronal,Deaminase, Asparagine,medac, Asparaginase
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent

Related Publications

A Nakamura, and M Tsurusawa, and A Kato, and T Taga, and Y Hatae, and M Miyake, and J Mimaya, and N Onodera, and A Watanabe, and T Watanabe, and H Kanegane, and T Matsushita, and A Iwai, and N Hyakuna, and K Gushi, and T Kawakami, and I Sekine, and O Izichi, and K Asami, and A Kikuta, and A Tanaka, and T Fujimoto, and
Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia.
November 2006, Blood,
A Nakamura, and M Tsurusawa, and A Kato, and T Taga, and Y Hatae, and M Miyake, and J Mimaya, and N Onodera, and A Watanabe, and T Watanabe, and H Kanegane, and T Matsushita, and A Iwai, and N Hyakuna, and K Gushi, and T Kawakami, and I Sekine, and O Izichi, and K Asami, and A Kikuta, and A Tanaka, and T Fujimoto, and
Prognostic irrelevance of CD34 expression in childhood B-precursor acute lymphoblastic leukemia.
June 1999, Haematologica,
A Nakamura, and M Tsurusawa, and A Kato, and T Taga, and Y Hatae, and M Miyake, and J Mimaya, and N Onodera, and A Watanabe, and T Watanabe, and H Kanegane, and T Matsushita, and A Iwai, and N Hyakuna, and K Gushi, and T Kawakami, and I Sekine, and O Izichi, and K Asami, and A Kikuta, and A Tanaka, and T Fujimoto, and
Prognostic significance of CD45 antigen expression in pediatric acute lymphoblastic leukemia.
July 2021, Blood cells, molecules & diseases,
A Nakamura, and M Tsurusawa, and A Kato, and T Taga, and Y Hatae, and M Miyake, and J Mimaya, and N Onodera, and A Watanabe, and T Watanabe, and H Kanegane, and T Matsushita, and A Iwai, and N Hyakuna, and K Gushi, and T Kawakami, and I Sekine, and O Izichi, and K Asami, and A Kikuta, and A Tanaka, and T Fujimoto, and
Differential microRNA expression in childhood B-cell precursor acute lymphoblastic leukemia.
January 2009, Pediatric hematology and oncology,
A Nakamura, and M Tsurusawa, and A Kato, and T Taga, and Y Hatae, and M Miyake, and J Mimaya, and N Onodera, and A Watanabe, and T Watanabe, and H Kanegane, and T Matsushita, and A Iwai, and N Hyakuna, and K Gushi, and T Kawakami, and I Sekine, and O Izichi, and K Asami, and A Kikuta, and A Tanaka, and T Fujimoto, and
Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia.
January 2007, Oncology reports,
A Nakamura, and M Tsurusawa, and A Kato, and T Taga, and Y Hatae, and M Miyake, and J Mimaya, and N Onodera, and A Watanabe, and T Watanabe, and H Kanegane, and T Matsushita, and A Iwai, and N Hyakuna, and K Gushi, and T Kawakami, and I Sekine, and O Izichi, and K Asami, and A Kikuta, and A Tanaka, and T Fujimoto, and
MHC variation and risk of childhood B-cell precursor acute lymphoblastic leukemia.
February 2011, Blood,
A Nakamura, and M Tsurusawa, and A Kato, and T Taga, and Y Hatae, and M Miyake, and J Mimaya, and N Onodera, and A Watanabe, and T Watanabe, and H Kanegane, and T Matsushita, and A Iwai, and N Hyakuna, and K Gushi, and T Kawakami, and I Sekine, and O Izichi, and K Asami, and A Kikuta, and A Tanaka, and T Fujimoto, and
JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia.
October 2017, Oncotarget,
A Nakamura, and M Tsurusawa, and A Kato, and T Taga, and Y Hatae, and M Miyake, and J Mimaya, and N Onodera, and A Watanabe, and T Watanabe, and H Kanegane, and T Matsushita, and A Iwai, and N Hyakuna, and K Gushi, and T Kawakami, and I Sekine, and O Izichi, and K Asami, and A Kikuta, and A Tanaka, and T Fujimoto, and
Aberrant CD2 expression in precursor-B acute lymphoblastic leukemia of childhood.
July 1996, American journal of hematology,
A Nakamura, and M Tsurusawa, and A Kato, and T Taga, and Y Hatae, and M Miyake, and J Mimaya, and N Onodera, and A Watanabe, and T Watanabe, and H Kanegane, and T Matsushita, and A Iwai, and N Hyakuna, and K Gushi, and T Kawakami, and I Sekine, and O Izichi, and K Asami, and A Kikuta, and A Tanaka, and T Fujimoto, and
Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia.
December 2012, Frontiers of medicine,
A Nakamura, and M Tsurusawa, and A Kato, and T Taga, and Y Hatae, and M Miyake, and J Mimaya, and N Onodera, and A Watanabe, and T Watanabe, and H Kanegane, and T Matsushita, and A Iwai, and N Hyakuna, and K Gushi, and T Kawakami, and I Sekine, and O Izichi, and K Asami, and A Kikuta, and A Tanaka, and T Fujimoto, and
Increased midkine gene expression in childhood B-precursor acute lymphoblastic leukemia.
August 2007, Leukemia research,
Copied contents to your clipboard!